High Genetic Risk for IBD Predicts Severe Disease Course, Danish Study of 8,300 Patients Finds

Approximately 60,000 Danes live with chronic inflammatory bowel disease - either Crohn's disease, which can inflame anywhere along the gastrointestinal tract, or ulcerative colitis, which affects the colon. Every year, 2,700 more are diagnosed, most of them young adults in their twenties to forties. But the disease behaves differently in different people. Some manage with medication and experience few disruptions to daily life. Others face repeated relapses, escalating treatments, and eventual surgery - sometimes including the removal of affected sections of intestine and the creation of a stoma.

The clinical problem is that, at the time of diagnosis, physicians have no reliable way to predict which trajectory any individual patient will follow. That leads to a pattern that serves almost no one well: some patients are overtreated with aggressive therapies they may not have needed, while others receive too little, too late - missing the window when early intervention could have preserved intestinal function.

What the Genetics Data Showed

A study from the DNRF Center of Excellence PREDICT at Aalborg University, just published in Gastroenterology, used a combination of national registry data and clinical material from Denmark's National Biobank to examine whether genetic risk scores calculated at diagnosis correlate with disease severity over time. The dataset included almost 8,300 people with chronic inflammatory bowel disease.

The central finding: patients with a higher polygenic risk score for IBD - a composite measure of how many risk-associated genetic variants a person carries - also had a significantly higher probability of experiencing a severe disease course. The genetic burden associated with susceptibility to developing the disease also predicts, in part, how bad that disease will be once it develops.

"We really lack a reliable clinical tool to choose the most appropriate strategy for the individual," said Marie Vibeke Vestergaard, the study's lead author and a PhD researcher at PREDICT. "The new findings represent some of the first steps towards truly personalized treatment of patients."

Connection to Earlier Work

This study builds on previous findings from the same research group. An earlier study showed that carrying the specific gene variant HLA-DRB1*01:03 substantially increases the probability that patients with ulcerative colitis will undergo major surgery. The current work extends that logic from a single gene to a polygenic framework, capturing the cumulative effect of many genetic variants rather than the impact of any individual one.

Together, the studies suggest that genomic data could eventually serve as a prognostic input at diagnosis - not to determine treatment, but to help stratify patients into higher and lower risk groups that warrant different levels of monitoring and early intervention intensity.

The Limitations Are Real

The study is observational. It demonstrates association between genetic risk and disease severity, not causation. The dataset, while large by IBD standards at 8,300 patients, is drawn from a single country with a largely homogeneous genetic background. Whether the same polygenic risk scores perform equally well in ethnically diverse populations requires separate validation.

Genetics is also only one input. The researchers are explicit that genetic risk scores account for some of the variation in disease course but not all of it. Environmental factors, microbiome composition, age at diagnosis, disease location, and treatment history all play roles. No existing polygenic risk score can yet predict disease trajectory with the precision required for individual clinical decisions - these tools work at the population level, not the individual level.

The next phase of the research will test which medications and treatment strategies work best for which genetically defined subgroups. That is a longer journey than deriving the risk scores themselves, but it is the step that would make the findings clinically actionable.